Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
Fuji Pharma has entered into an agreement with Luxemburg-based Alvotech Holdings to acquire a 4.2% stake in the biopharma for US$50 million. Earlier in November, the Japanese company closed an exclusive partnership deal with Alvotech Holdings’ Iceland subsidiary for the…
To read the full story
Related Article
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
- Fuji Pharma In-Licenses Sixth Biosimilar from Alvotech
February 25, 2022
- Fuji Pharma to File Biosimilars for Japan Approval by 2021: President
May 20, 2019
- Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
December 26, 2018
- Fuji Pharma to Bolster Biosimilar Business as New Core
November 20, 2018
BUSINESS
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
- Fujifilm Invests in Austria’s Valanx Biotech to Boost ADC Technology
March 13, 2026
- Merck, CDMO Cyto-Facto Join Hands on Cell and Gene Therapy
March 13, 2026
- Anti-PD-1 Agonist Antibody Enters PI in Australia for Autoimmune Diseases: Meiji
March 13, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…